GREEN CROSS CELL CORPORATION

031390 KRX Pharmaceuticals Pharmaceuticals
KRX

Strengths

  • Moderate debt: debt-to-equity of 0.71.
  • Pays a dividend (yield about 0.2%).
  • Has paid a dividend in each of the last 4 years on record.

!Watch-points

  • Thin interest cover: operating profit covers interest only about 0.5 times.
  • Return on equity is on the lower side at 2%.
  • Return on capital employed is on the lower side at 0.9%.
  • Net profit margin is slim at 4.9%.
  • Profit growth has been slow over five years (about -82% a year).

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreDistress zone
0.56

In Altman’s study, scores in this range were associated with a higher incidence of financial distress.

Computed without the market-value term.

Piotroski F-ScoreWeak
2 / 4

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 4 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Book Value₩ 8,092.46
Dividend Yield0.20%
ROCE0.93%
ROE1.97%
Debt to Equity0.71
Current Ratio1.39
EPS₩ 163.00
PAT Margin4.93%
ICR0.52
Compounded Sales Growth
10 Years
5 Years 7.74%
3 Years
TTM
Compounded Profit Growth
10 Years
5 Years -81.78%
3 Years
TTM
Stock Price CAGR
10 Years
5 Years
3 Years
1 Year
Return on Equity
10 Years
5 Years
3 Years
Last Year 1.97%
Educational data only. Not a recommendation to buy, sell or hold any security.